ArticleCancer medicine2023

Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.

Yue Hao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.